dhodh-in-1

DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM. DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway.

RORγt DHODH-IN-1 (compound (R)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.083 μM) and DHODH (IC50: 0.172 μM), exhibiting significant in vivo anti-inflammatory effects.

CHIKV-IN-2, a chemical compound, exhibits potent inhibitory activity against the enzyme Dihydroorotate Dehydrogenase (DHODH), crucial for pyrimidine synthesis affecting various viruses' replication. It serves as an effective Chikungunya virus (CHIKV) inhibitor, demonstrating significant cellular antiviral activity (EC90=270 nM) and enhanced liver microsomal stability[1].

RORγt DHODH-IN-3 (compound (S)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.098 μM) and DHODH (IC50: 0.432 μM) with significant in vivo anti-inflammatory effects.

DHODH-IN-24 (compound 16) serves as a powerful inhibitor of human dihydroorotate dehydrogenase (DHODH), exhibiting an IC50 value of 91 nM [1].

RORγt DHODH-IN-2 (compound 1) is a potent dual inhibitor of RORγt and DHODH, useful for studying inflammatory bowel disease (IBD).

DHODH-IN-25 (Compound 25) serves as an orally active inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting a potent IC50 of 5.4 nM against human DHODH. It is applicable in research related to acute myeloid leukemia (AML) [1].

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity, showing potential as a first-in-class candidate in AML [Acute Myeloid Leukemia].

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].